REG-Arix Bioscience PLC Result of Annual General Meeting

Arix BioscienceAnnouncement

23/05/2023 16:45

============

  Arix Bioscience PLC (ARIX)
  Result of Annual General Meeting

  23-May-2023 / 16:30 GMT/BST

  ══════════════════════════════════════════════════════════════════════════════

   

                               Arix Bioscience plc

                                         

                         Result of Annual General Meeting

   

  LONDON, 23  May 2023:  Arix Bioscience  plc (“Arix”  or the  “Company”)  (LSE:
  ARIX), a  transatlantic  venture  capital  company  focused  on  investing  in
  breakthrough biotechnology  companies, announces  that at  its Annual  General
  Meeting (the "Meeting") duly convened and  held today, all resolutions as  set
  out on the notice of meeting were duly passed by way of a poll. Resolutions  1
  to 11 were passed as ordinary resolutions. Resolutions 12 to 15 were passed as
  special resolutions.

   

  Full details of the poll results are set out below and will also be  available
  on the Company's .

   

                                       VOTES            TOTAL     % of   VOTES
  No  RESOLUTION  VOTES FOR     %     AGAINST    %      VOTES     ISC   WITHHELD
                                                                 VOTED
      To receive
         the
      Directors'
      Report and                                                            
     the accounts
  1     of the    68,931,411 100.00%   3,441   0.00%  68,934,852 53.28%  8,440
     Company for
       the year                                                             
       ended 31
       December
         2022
      To approve                                                            
         the
  2   Directors'  61,073,950 89.25%  7,358,207 10.75% 68,432,157 52.89% 511,135
     Remuneration
        Report                                                              
     To re-elect                                                            
      Peregrine
  3   Moncreiffe  68,099,019 98.79%   834,821  1.21%  68,933,840 53.28%  9,452
         as a
       Director                                                             
     To re-elect                                                            
       Maureen
  4  O'Connell as 68,894,053 99.94%   42,077   0.06%  68,936,130 53.28%  7,162
      a Director
                                                                            
     To re-elect                                                            
        Isaac
  5  Kohlberg as  68,900,656 99.98%   17,184   0.02%  68,917,840 53.26%  25,452
      a Director
                                                                            
     To re-elect                                                            
     Robert Lyne
  6      as a     68,902,689 99.95%   31,595   0.05%  68,934,284 53.28%  9,008
       Director
                                                                            
     To elect Dr.                                                           
     Debra Barker
  7      as a     68,907,528 99.95%   32,248   0.05%  68,939,776 53.28%  3,516
       Director
                                                                            
       To elect                                                             
     Andrew Smith
  8      as a     68,921,195 99.98%   13,089   0.02%  68,934,284 53.28%  9,008
       Director
                                                                            
      To appoint                                                            
      BDO LLP as
  9  auditors of  68,929,881 99.99%    7,445   0.01%  68,937,326 53.28%  5,966
     the Company
                                                                            
     To authorise
      the Audit                                                             
       and Risk
  10 Committee of 68,934,245 100.00%   2,013   0.00%  68,936,258 53.28%  7,034
     the Company
      to fix the                                                            
      auditor's
     remuneration
     To authorise                                                           
         the
  11 Directors to 65,989,256 95.72%  2,950,520 4.28%  68,939,776 53.28%  3,516
     allot shares
                                                                            
     Authority to                                                           
       disapply
  12  statutory   62,199,252 90.23%  6,734.680 9.77%  68,933,932 53.28%  9,360
     pre‐ emption
        rights                                                              
      Additional                                                            
     authority to
  13   disapply   62,202,105 90.23%  6,731,827 9.77%  68,933,932 53.28%  9,360
      statutory
     pre‐ emption                                                           
        rights
     To authorise                                                           
     the Company
  14 to purchase  68,921,128 99.98%   17,177   0.02%  68,938,305 53.28%  4,987
       its own
        shares                                                              
     Authority to
        call a
       general
       meeting,                                                             
      other than
  15  an annual   68,145,351 98.85%   792,954  1.15%  68,938,305 53.28%  4,987
       general
     meeting, on                                                            
       not less
       than 14
     clear days'
        notice

   

  In accordance with Listing Rule 9.6.2, copies of resolutions passed at the
  Meeting concerning items other than ordinary business will shortly be
  available for inspection on the National Storage Mechanism, which can be
  accessed at .

  The full text of the resolutions considered at the AGM are contained in the
  Notice of AGM, published on 25 April 2023, which is available on Arix investor
  relations .

                                       ENDS 

   

   

  Enquiries

  For more information on Arix, please contact:

   

  Arix Bioscience plc

  +44 (0)20 7290 1050

  ir 1 @arixbioscience.com

   

  Powerscourt Group

  Sarah MacLeod, Ibrahim Khalil, Nick Johnson

  +44 (0)20 7250 1446

   2 arix@powerscourt-group.com

   

  About Arix Bioscience plc

  Arix Bioscience plc is a transatlantic venture capital company focused on
  investing in breakthrough biotechnology companies around cutting-edge advances
  in life sciences.

   

  We collaborate with exceptional entrepreneurs and provide the capital,
  expertise, and networks to help accelerate their ideas into important new
  treatments for patients. As a listed company, we are able to bring this
  exciting growth phase of our industry to a broader range of investors.
   3 www.arixbioscience.com

   

   

  ══════════════════════════════════════════════════════════════════════════════

  Dissemination of a Regulatory Announcement, transmitted by EQS Group.
  The issuer is solely responsible for the content of this announcement.

  ══════════════════════════════════════════════════════════════════════════════

   ISIN:           GB00BD045071
   Category Code:  RAG
   TIDM:           ARIX
   LEI Code:       213800OVT3AHQCXNIX43
   OAM Categories: 3.1. Additional regulated information required to be
                   disclosed under the laws of a Member State
   Sequence No.:   245804
   EQS News ID:    1639935


    
   End of Announcement EQS News Service

   ══════════════════════════════════════════════════════════════════════════

    4 fncls.ssp?fn=show_t_gif&application_id=1639935&application_name=news&site_id=reuters9

References

   Visible links
   1. mailto:charlotte@arixbioscience.com
   2. mailto:arix@powerscourt-group.com
   3. https://eqs-cockpit.com/cgi-bin/fncls.ssp?fn=redirect&url=889c637ce21c3a47a35c39202ebd9825&application_id=1639935&site_id=reuters9&application_name=news


============